Kind of a crappy article. It focuses on new drug innovation when most of the markup we are seeing in the US is for old drugs. As an individual you can't negotia

Kind of a crappy article. It focuses on new drug innovation when most of the markup we are seeing in the US is for old drugs. As an individual you can't negotiate when you need a drug. It's up to a regulatory body to make sure the manufacturers aren't exploiting their position in the market.